EGFR and non-small cell lung carcinoma: In the FLAURA study, first-line treatment of EGFR (exon 19 deletion or L858R) mutant NSCLC with the third generation tyrosine kinase inhibitor osimertinib resulted in a significant improvement in median PFS and OS of 19 months and 39 months, respectively [13,14].